Syntekabio, Inc. announced that it has received $11.2 million in funding from Altos Ventures, Smilegate Investment, Inc., YOZMA GROUP KOREA Co.,Ltd., Korea Development Bank, Investment Arm, Korea Fixed-Income Investment Advisory
May 06, 2018
Share
Syntekabio, Inc. has announced that it has received $11.2 million in its series B round of funding led by new investor Smilegate Investment, Inc. on May 7, 2018. The transaction included participation from new investors, YOZMA GROUP KOREA Co.,Ltd., Korea Development Bank, Investment Arm, Korea Fixed-Income Investment Advisory and existing investor, Altos Ventures. The company has raised upwards of $19 million in funding till date.
Syntekabio,Inc. is a Korea-based company principally engaged in the provision of database and software. The Company develops and sells software such as personal algorithm dielectric map platform (PMAP) using artificial intelligence (AI) technology, provides clinical trial modeling and genome analysis services through big data. The analysis results are used to diagnose genetic diseases, select biomarker treatments and predict disease risk. In addition, the Company develops AI drug development technology, provides research services for candidate substances of immuno-cancer drugs.
Syntekabio, Inc. announced that it has received $11.2 million in funding from Altos Ventures, Smilegate Investment, Inc., YOZMA GROUP KOREA Co.,Ltd., Korea Development Bank, Investment Arm, Korea Fixed-Income Investment Advisory
SYNTEKABIO, INC. 
